Dr. Pattee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2631 S 70th St
Lincoln, NE 68506Phone+1 402-483-7226Fax+1 402-483-5440
Education & Training
University of ColoradoResidency, Neurology, 1987 - 1990
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1986 - 1987
McGovern Medical School at UTHealthClass of 1986
Certifications & Licensure
NE State Medical License 1991 - 2026
CO State Medical License 1988 - 2005
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Clinical Trial Nuedexta in Subjects With ALS Start of enrollment: 2013 Apr 01
- Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- ALSUntangled #78: Zinc.Benjamin Helmold, George Nathaniel, Paul Barkhaus, Tulio Bertorini, Mark Bromberg
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2025-03-14 - 2 citationsCNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17 - Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17
Journal Articles
- Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral SclerosisSabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine
Press Mentions
Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial of RADICAVA ORS® (Edaravone) in ALSFebruary 27th, 2023- Alliance Backs SLE Research by Minority ScientistsJune 14th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
